Abl tyrosine kinase regulates endocytosis of the epidermal growth factor receptor

被引:80
|
作者
Tanos, Barbara [1 ]
Pendergast, Ann Marie [1 ]
机构
[1] Duke Univ, Med Ctr, Dept Pharmacol & Canc Biol, Durham, NC 27710 USA
关键词
D O I
10.1074/jbc.M603126200
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Signal attenuation from ligand-activated epidermal growth factor receptor ( EGFR) is mediated in part by receptor endocytosis and trafficking to the lysosomal degradative compartment. Uncoupling the activated EGFR from endocytosis and degradation has emerged as a mechanism for oncogenic activation of the EGFR. The Abl nonreceptor tyrosine kinase is activated by ligand-stimulated EGFR, but the role of Abl in EGFR signaling has not been defined. Here we uncovered a novel role for the activated Abl kinase in the regulation of EGFR endocytosis. We show that activated Abl impairs EGFR internalization. Moreover, we show that activated Abl phosphorylates the EGFR primarily on tyrosine 1173, and that mutation of this site to phenylalanine restores ligand-dependent endocytosis of the EGFR in the presence of activated Abl. Furthermore, we show that activated Abl allows the ligand-activated EGFR to escape Cbl-dependent down-regulation by inhibiting the accumulation of Cbl at the plasma membrane in response to epidermal growth factor stimulation and disrupting the formation of the EGFR center dot Cbl complex without affecting Cbl protein stability. These findings reveal a novel role for Abl in promoting increased cell-surface expression of the EGFR and suggest that Abl/EGFR signaling may cooperate in human tumors.
引用
收藏
页码:32714 / 32723
页数:10
相关论文
共 50 条
  • [31] Evolving Landscape of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors
    Kao, Steven C.
    Boyer, Michael J.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (27) : 3233 - 3234
  • [32] PHOSPHORYLATION OF CALMODULIN BY THE EPIDERMAL-GROWTH-FACTOR-RECEPTOR TYROSINE KINASE
    BENGURIA, A
    HERNANDEZPERERA, O
    MARTINEZPASTOR, MT
    SACKS, DB
    VILLALOBO, A
    EUROPEAN JOURNAL OF BIOCHEMISTRY, 1994, 224 (03): : 909 - 916
  • [33] Epidermal growth factor receptor tyrosine kinase inhibitors in cancer therapy
    Adjej, AA
    DRUGS OF THE FUTURE, 2001, 26 (11) : 1087 - 1092
  • [34] Evaluation of novel epidermal growth factor receptor tyrosine kinase inhibitors
    Rae, JM
    Lippman, ME
    BREAST CANCER RESEARCH AND TREATMENT, 2004, 83 (02) : 99 - 107
  • [35] Diabetic cardiomyopathy: Role of epidermal growth factor receptor tyrosine kinase
    Xu, Zheng
    Cai, Lu
    JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY, 2015, 84 : 10 - 12
  • [36] A SPECIFIC INHIBITOR OF THE EPIDERMAL GROWTH-FACTOR RECEPTOR TYROSINE KINASE
    FRY, DW
    KRAKER, AJ
    MCMICHAEL, A
    AMBROSO, LA
    NELSON, JM
    LEOPOLD, WR
    CONNERS, RW
    BRIDGES, AJ
    SCIENCE, 1994, 265 (5175) : 1093 - 1095
  • [37] Epidermal growth factor receptor tyrosine kinase inhibitors as anticancer agents
    Ciardiello, F
    DRUGS, 2000, 60 (Suppl 1) : 25 - 32
  • [38] Epidermal Growth Factor Receptor Tyrosine Kinase as a Target for Anticancer Therapy
    Eric Raymond
    Sandrine Faivre
    Jean Pierre Armand
    Drugs, 2000, 60 : 15 - 23
  • [39] Control of epidermal growth factor receptor endocytosis by receptor dimerization, rather than receptor kinase activation
    Wang, Q
    Villeneuve, G
    Wang, ZX
    EMBO REPORTS, 2005, 6 (10) : 942 - 948
  • [40] The receptor tyrosine kinase AXL mediates nuclear translocation of the epidermal growth factor receptor
    Brand, Toni M.
    Iida, Mari
    Corrigan, Kelsey L.
    Braverman, Cara M.
    Coan, John P.
    Flanigan, Bailey G.
    Stein, Andrew P.
    Salgia, Ravi
    Rolff, Jana
    Kimple, Randall J.
    Wheeler, Deric L.
    CANCER RESEARCH, 2017, 77